Interestingly, Hsieh et al. reported that PBRM1 mutations were associated with longer progression free survival (PFS) in metastatic RCC patients treated with first-line everolimus in the RECORD-3 trial [15]. This evidence concerns the gene PBRM1 and renal cell carcinoma.